Qushi Huayu Decoction inhibits protein and gene expression of cathepsin B in HepG2 cells induced by free fatty acids

Chinese Journal of Integrative Medicine

Volumn 16, Issue 6, 2010, Pages 518-524

  Feng, Qin ^a   Cheng, Yang ^a   Hu, Yi Yang ^a   Zhang, Hui ^a   Peng, Jing Hua ^a   Zhang, Ning ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cathepsin B; Free fatty acid; Hepatic lipotoxicity; Qushi Huayu Decoction

Indexed keywords

CATHEPSIN B; FATTY ACID; GASTROINTESTINAL AGENT; I KAPPA B; MESSENGER RNA; QUSHI HUAYU; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LYSOSOME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STEATOSIS; WESTERN BLOTTING;

CATHEPSIN B; CELL DEATH; DRUGS, CHINESE HERBAL; FATTY ACIDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEP G2 CELLS; HUMANS; I-KAPPA B PROTEINS; L-LACTATE DEHYDROGENASE; RNA, MESSENGER; SUBCELLULAR FRACTIONS; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952541848     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-010-0568-z     Document Type: Article

References (32)

1. Feng Q, Zhang H, HU YY, Liu CH, Liu P. Effect of Qushi Huayu Decoction on prevention and treatment of fatty liver induced by high-fat diet in rats. Chin J Integr Tradit West Med Liver Dis (Chin) 2006;1:26-29.
2. Zhang H, Feng Q, Hu yy, Liu CH, Liu P. Prevention and treatment of "Qushi Huayu Decoction" on fatty liver of rats induced by carbon tetrachloride along with high-fat and low-protein diet. Shanghai J Tradit Chin Med (Chin) 2006;40:52-55.
3. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway. Hepatology 2004;40:185-194. (Pubitemid 38868937)
4. Feldstein AE, Werneburg NW, Li Z, Bronk SF, Gores GJ. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol 2006;290:G1339-G1346. (Pubitemid 43788317)
5. Heider JG, Boyett RL. The picomole determination of free and total cholesterol in cells in culture. J Lipid Res 1978;19:514-518. (Pubitemid 8356055)
6. Cheng Y, Ping J, Xu HD, Fu HJ, Zhou ZH. Synergestic effect of a novel oxymatrine-baicalin combination against HBV replication, alpha smooth muscle actin expression and type I collagen synthesis in vitro. World J Gastroenterol 2006;12:5153-5159. (Pubitemid 44355911)
7. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
8. Neuschwander-Tetri B, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37:1202-1219. (Pubitemid 36538699)
9. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006;82:315-322. (Pubitemid 43780662)
10. Sherif. Nonalcoholic fatty liver disease and obesity. Nutrit Clin Pract 2007;22:1-10.
11. Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006;29:1845-1850. (Pubitemid 44156640)
12. Day C, James O. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-845.
13. Michael W. Bradbury. Lipid metabolism and liver inflammation. hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol 2006;290:G194-G198.
14. Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metabol 2006; 91:4753-4761. (Pubitemid 44917301)
15. Schwabe RF, Brenner DA. Mechanisms of liver injury. TNF-α-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006;290:G583-G589.
16. Han D, Hanawa N, Saberi B, Kaplowitz N. Mechanisms of liver injury. III. Role of glutathione redox status in liver injury. Am J Physiol Gastrointest Liver Physiol 2006;291:G1-G7. (Pubitemid 44024656)
17. Reddy JK, Rao MS. Lipid Metabolism and liver inflammation II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006;290:G852-G858.
18. Malhi H, Bronk SF, Werneburg MW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte Lipoapoptosis. J Biol Chem 2006;281:12093-12101. (Pubitemid 43855473)
19. Unger RH. Lipotoxic diseases. Annu Rev Med, 2002;53:319-336. (Pubitemid 34177884)
20. Unger RH. The physiology of cellular liporegulation. Annu Rev Physiol 2003;65:333-347. (Pubitemid 38249157)
21. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 2002;1585:202-212. (Pubitemid 36092084)
22. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003;14:398-403. (Pubitemid 37392211)
23. Wullaert A, Loo GV, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-B: effects on liver homeostasis and beyond. Endocr Rev 2007;28:365-386. (Pubitemid 46984825)
24. Werneburg N, Guicciardi ME, Yin XM, Gores GJ. TNF-alpha-mediated lysosomal permeabilization is FAN and caspase 8/Bid dependent. Am J Physiol Gastrointest Liver Physol 2004;287:G436-G443. (Pubitemid 38955264)
25. Guicciardi ME, Miyoshi H, Bronk SF, Gores GJ. Cathepsin B knockout mice are resistant to tumor necrosis factor-α-mediated hepatocyte apoptosis and liver injury. Am J Pathol 2001;159:2045-2054. (Pubitemid 33104259)
26. Liu H, Jones BE, Bradham C, Czaja MJ. Increased cytochrome P-450 2E1 expression sensitizes hepatocytes to c-Jun-mediated cell death from TNF-α. Am J Physiol Gastrointest Liver Physiol 2002;282:G257-G266. (Pubitemid 34651682)
27. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-350. (Pubitemid 36152533)
28. Im E, Venkatakrishnan A, Kazlauskas A. Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Molecul Biol Cell 2005;16:3488-3500. (Pubitemid 41077063)
29. Vasiljeva O, Papazoglou A, Krüger A, Brodoefel H, Korovin M, Deussing J, et al. Tumor cell-derived and macrophage-derived cathepsin B promotesprogression and lung metastasis of mammary cancer. Cancer Res 2006;66:5242-5250. (Pubitemid 43844948)
30. Baskin-Bey ES, Canbay A, Bronk SF, Werneburg N, Guicciardi ME, Nyberg SL, et al. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2005;288:G396-G402. (Pubitemid 40129592)
31. Foghsgaard L, Wissing D, Mauch D, Lademann U, Bastholm L, Boes M, et al. Cathepsin B act as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol 2001;153:999-1009. (Pubitemid 34289239)
32. Canbay A, Guicciardi ME, Higuchi H, Feldstein A, Bronk SF, Rydzewski R, et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest 2003;112:152-159. (Pubitemid 38056351)